U.S. Markets closed

Caladrius Biosciences, Inc. (CLBS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.4264-0.0858 (-16.75%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5122
Bid0.0000 x 1800
Ask0.0000 x 1000
Day's Range0.3820 - 0.6497
52 Week Range0.3820 - 18.6000
Avg. Volume80,533
Market Cap25.49M
Beta (5Y Monthly)0.99
PE Ratio (TTM)N/A
EPS (TTM)-0.5280
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
  • GlobeNewswire

    Life Sciences Virtual Investor Conference: Presentations Now Available for On-Demand Viewing

    NEW YORK, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the September Life Sciences Virtual Investor Conference are now available for on-demand viewing. REGISTER NOW OR LOGIN AT: company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Companies are accep

  • GlobeNewswire

    Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics

    Company to commence trading on The Nasdaq Capital Market under Ticker Symbol “LSTA” Lisata has approximately $76 million in cash and investments following transaction close Lisata strengthens Board of Directors and Executive Leadership Team, appointing seasoned biopharmaceutical and clinical development industry executives BASKING RIDGE, N.J. and SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius”) and Cend Therapeutics, Inc. (“Cend”) today annou

  • GlobeNewswire

    Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics

    All Merger-related proposals approved at the Annual Meeting of StockholdersBASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders held September 13, 2022, its stockholders approved all of the merger-related proposals, including: (i) the Agreement and Plan of Merger and Reorganiz